Loading
NASDAQHealthcareBiotechnology
Latest quote
$6.86
+$0.06 · +0.88%
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Regular session
$6.86
+$0.06 · +0.88%
Regular session · ET · Market data may be delayed.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Day range
Current $6.86
52-week range
Current $6.86
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
23
Expensive
Sentiment
61
Bullish
Risk
71
High Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Day range
Current $6.86
52-week range
Current $6.86
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.50
446.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.91M0.00%2.3T USD0.03%$381.39+0.48%
iShares Russell 2000 ETFIWM3.33M0.00%77.7B USD0.19%$278.79+0.44%
Vanguard Extended Market ETFVXF3.04M0.00%95.4B USD0.05%$234.69+0.67%
iShares Russell 2000 Value ETFIWN1M0.01%13.75B USD0.24%$211.09+0.07%
Simplify Propel Opportunities ETFSURI689.21K0.92%74.84M USD2.82%$17.12+0.21%
iShares Micro-Cap ETFIWC410.62K0.03%1.32B USD0.60%$182.91+0.06%
iShares Russell 2000 Growth ETFIWO336.65K0.00%14.04B USD0.24%$355.94+0.70%
Franklin Small Cap Enhanced ETFFSML309.6K0.21%150.37M USD0.45%$29.12+0.72%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOFranklin Small Cap Enhanced ETFFSMLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
